Edit, not 100 percent sure why the priority all th

Edit, not 100 percent sure why the priority all the sudden, but yes it’s been mentioned several times during CCs. I believe Kelly specifically mentioned it during a CC and also said something to the effect of strong signals in this area.

I’d have to go looking for the CC and what exactly was said but it’s definitely been on managements radar, maybe we haven’t discussed much about it much here.

MGK can probably quote some stuff from the CCs. If not I’ll look later.

“Back around August-September 2023, CytoDyn in fact was originally slated to participate in a large MD Anderson ColoRectal Cancer clinical trial in combination with Keytruda. Originally, Scott Kelly was the key individual who arranged the murine study with Keytruda and made it a reality. Cyrus Arman though, was the man responsible for taking the results of that murine study and getting the CRC clinical trial all worked out. Unfortunately, CytoDyn shut down Cyrus' plans; they shut down his baby, the CRC clinical trial at MD Anderson; (reading that highlighted post now in retrospect proves interesting). In consideration of ohm20's reasoning, which I completely do agree with, I hypothesize that the murine study at MD Anderson had determined that leronlimab did all the meaningful work. This would be of no big surprise because in addition to being a direct CCR5 blockade, leronlimao also acts as an indirect blockade of PD-1. This would seem to indicate that Keytruda wouldn't have done much at all in terms of shrinking the impossible to treat MicroSatellite Stable tumors, (the tumors which vastly outnumber the treatable MicroSatellite Unstable tumors 5:7).“